Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Edition  2016: Volume 21/ Issue 32 Article 2
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 21, Issue 32, 11 August 2016
Rapid communication
Nicastri, Castilletti, Liuzzi, Iannetta, Capobianchi, and Ippolito: Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016

+ Author affiliations


Citation style for this article: Nicastri E, Castilletti C, Liuzzi G, Iannetta M, Capobianchi MR, Ippolito G. Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016. Euro Surveill. 2016;21(32):pii=30314. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.32.30314

Received:06 July 2016; Accepted:09 August 2016


Case description and laboratory investigations

In the second half of January 2016, a previously healthy man in his early 30s reported to the National Institute of Infectious Diseases in Rome, Italy, a history of five-day self-limiting febrile syndrome (< 38 °C) associated with asthenia and an erythematous rash during a stay in Haiti from mid-January to early February 2016. Zika virus (ZIKV) infection was diagnosed in Haiti by ZIKV-specific IgM serology four days after symptom onset (Figure). He returned to Italy 14 days after symptom onset.

Figure

Laboratory findings related to Zika virus infection in a traveller returning from Haiti to Italy, February–July 2016

/images/dynamic/articles/22554/16-00455-fa

CT: threshold cycle; IFA: indirect immunofluorescence assay; NT: not tested; Neg: negative; Pos: positive; RT-PCR: reverse transcription-PCR; ZIKV: Zika virus; MNT: microneutralisation test.

Dengue virus and chikungunya virus infections were ruled out following testing of serum and urine samples taken 17 days after symptom onset by both qualitative real-time reverse transcription (RT)-PCR (RealStar Dengue RT-PCR Kit and RealStar Chikungunya RT-PCR Kit, altona Diagnostics, Germany) and serology (indirect immunofluorescence assay (IFA), Arbovirus Fever Mosaic 2, IgM and IgG, Euroimmun, Germany). ZIKV serology (IFA, Arbovirus Fever Mosaic 2, Euroimmun) was positive: ZIKV IgM and IgG antibody titres were 1:160 and 1:640, respectively. Serum ZIKV-specific neutralising antibodies were confirmed by microneutralisation test [1]. ZIKV real-time RT-PCR (RealStar Zika Virus RT-PCR Kit, altona Diagnostics) in saliva was positive with a threshold cycle (CT) value of 36.4; serum and urine samples were both negative.

Testing of convalescent sera taken 91 and 134 days after symptom onset were ZIKV real-time RT-PCR negative. On day 91, the test was positive for urine, saliva and semen samples, with CT values of 36.1, 35.4, and 29.6, respectively. On day 134, only a semen sample was positive (CT: 32.5). At the subsequent follow-up, on day 188, a semen sample was again positive (CT: 30.2); the patient is still under evaluation. The patient was not affected by any chronic disease or immunological impairment.

All samples were tested also using a pan-flavivirus NS5 nested RT-PCR (modified from [2]), followed by sequencing of the amplicons (data not shown) to exclude any sample mismatch.

On day 91, ZIKV IgM and IgG titres were 1:40 and 1:1,280, and on day 134, 1:20 and 1:2,560, respectively.

ZIKV isolation on Vero-E6 cells was attempted with all the collected samples. Briefly, bodily samples were diluted 1:5 in serum-free Dulbecco’s-modified Eagle’s medium (D-MEM) with antibiotics, inoculated into Vero-E6 cells that were 24 hours-old and then incubated for 60 minutes at 37 °C. After incubation, D-MEM with 2% heat-inactivated fetal bovine serum was added. The cells were followed daily for the appearance of cytopathic effects. After seven days, the cells were subcultured by scraping them and adding fresh cells. Each blind subpassage (three times) was checked for the presence of ZIKV RNA by real-time RT-PCR. No ZIKV isolates were obtained from samples collected during the convalescent phase.

Throughout the course of the ZIKV infection, the patient always had protected sexual intercourse with his spouse, using condoms. His spouse did not report ZIKV-related symptoms, and as at 18 July 2016, her ZIKV serology was still negative.

Background

Zika virus is a single-stranded RNA virus (genus Flavivirus) mainly transmitted by the Aedes mosquito, as well as through sexual contact with symptomatic and, possibly, asymptomatic individuals [3,4]. This non-vector-related mode of transmission was first described in 2008 in the United States [5] and was then reported in several other countries [3,4,6,7].

ZIKV RNA can be detected in different bodily fluids with a wide range of viral loads, depending on the sampling time since acute infection [8,9]. ZIKV from human semen samples has been isolated in African green monkey Vero cells [10] and higher viral loads have been detected in sperm compared with other bodily samples during the convalescent phase [11]. Previous reports have shown that ZIKV RNA has been detected in semen up to day 62 after symptom onset [12-14]. Taken together, these data suggest that virus could replicate specifically in the male genital tract and may persist in semen, with implications for potential male-to-female sexual transmission, even in the absence of haematospermia.

Discussion

In previous reports, convalescent phase saliva and urine samples were positive by ZIKV real-time RT-PCR in 39 days after symptom onset [3,14].

For the case described here, detection of ZIKV RNA in urine and saliva 91 days after symptom onset and in semen up to day 134 might indicate a possible role played by other non-vector modes of transmission during kissing or vaginal, oral and anal sex. Because of the lack of virus isolation from all the collected samples, we cannot definitively state that saliva, urine and semen represent a potential source of ZIKV that could be transmitted without a vector. During the outbreak in French Polynesia, ZIKV was more frequently detected in saliva than in blood after the first week from symptom onset [13] and it was isolated on day 6 from the saliva of a patient during acute ZIKV infection [14]. No cases involving ZIKV transmission through biological fluids other than semen have been reported, but potential transmission of ZIKV through saliva warrants investigation [15].

The detection of ZIKV RNA in semen up to day 134 might indicate a prolonged potential risk for sexual transmission, for a period longer than previously reported [12]. In reports of Ebola virus disease, suspected sexual transmission of Ebola virus occurred 179 days after onset of the disease [16] and Ebola virus RNA has been detected in semen for 4–6 months after disease onset in 43% of survivors [17].

The lack of isolation of ZIKV from the various biological samples of our patient, during the convalescent phase, is not unexpected. The high CT values found are consistent with a low Zika viral load during the convalescent phase of infection, making it difficult to obtain viral cultures and thus sequence data.

Because of prolonged detection of ZIKV RNA and isolation of replication-competent virus in semen [11,13], the testes are considered an immunoprivileged replication site for ZIKV [18]. Seminal shedding of ZIKV seems to coincide with the duration of spermatogenesis (69–80 days), suggesting a hypothesis of infection of sperm progenitors and viral shedding during the differentiation process [18]. Our results showed the persistence of ZIKV RNA for 188 days after symptom onset, but this is not sufficient to support a hypothesis of ZIKV RNA being present in sperm progenitors until spermatozoa are fully differentiated and eliminated. Further studies are needed in order to understand persistence of ZIKV in semen and the potential risk of ZIKV sexual transmission.

Public health impact

The European Centre for Disease Prevention and Control and the World Health Organization recommend that all travellers returning from areas with ongoing ZIKV transmission should adopt safer sex practices or consider abstinence for at least eight weeks after their return [4,19]; if men have ZIKV-related symptoms, they should adopt safer sex practices or consider abstinence for at least six months.

Considering the 80% incidence rate of asymptomatic ZIKV infection [20], further studies are needed to assess viral persistence in asymptomatic men and the potential risk for sexual transmission and fetal abnormalities following infection during pregnancy. The prolonged genital shedding reported here may have implications for screening measures to detect ZIKV RNA for semen cryopreservation in sperm banks [21].


Acknowledgements

This study was funded by Ricerca Corrente of the Italian Ministry of Health.

Conflict of interest

None declared.

Authors’ contributions

Emanuele Nicastri was the physician in charge of the patient, Giuseppina Liuzzi was the physician in charge of the spouse of the patient; Concetta Castilletti was the virologist in charge of the virological assay for Zika virus diagnosis, Marco Iannetta wrote the manuscript, Maria R. Capobianchi, who is the person responsible for the virology laboratory unit, and Giuseppe Ippolito, who supervises all the clinical and translational research on emerging and re-emerging pathogens, contributed to the discussion and reviewed the manuscript.


References

  1. Papa A, Perperidou P, Tzouli A, Castilletti C. West Nile virus--neutralizing antibodies in humans in Greece.Vector Borne Zoonotic Dis. 2010;10(7):655-8. Available from: DOI: 10.1089/vbz.2010.0042 PMID: 20738157

  2. Moureau G, Temmam S, Gonzalez JP, Charrel RN, Grard G, de Lamballerie X. A real-time RT-PCR method for the universal detection and identification of flaviviruses.Vector Borne Zoonotic Dis. 2007;7(4):467-77. Available from: DOI: 10.1089/vbz.2007.0206 PMID: 18020965

  3. Fréour T, Mirallié S, Hubert B, Splingart C, Barrière P, Maquart M,  et al.  Sexual transmission of Zika virus in an entirely asymptomatic couple returning from a Zika epidemic area, France, April 2016. Euro Surveill. 2016;21(23):30254. DOI: 10.2807/1560-7917.ES.2016.21.23.30254

  4. World Health Organization (WHO). Prevention of sexual transmission of Zika virus. Interim guidance update. 7 June 2016. WHO/ZIKV/MOC/16.1 Rev.2. Geneva: WHO; 2016. Available from: http://apps.who.int/iris/bitstream/10665/204421/1/WHO_ZIKV_MOC_16.1_eng.pdf?ua=1</eref

  5. Foy BD, Kobylinski KC, Chilson Foy JL, Blitvich BJ, Travassos da Rosa A, Haddow AD,  et al.  Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis. 2011;17(5):880-2. DOI: 10.3201/eid1705.101939

  6. Frank C, Cadar D, Schlaphof A, Neddersen N, Günther S, Schmidt-Chanasit J, Tappe D. Sexual transmission of Zika virus in Germany, April 2016. Euro Surveill. 2016 9;21 (23):pii=30252. http://dx.doi.org/10.2807/1560-7917.ES.2016.21.23.30252

  7. Turmel JM, Abgueguen P, Hubert B, Vandamme YM, Maquart M, Le Guillou-Guillemette H, Leparc-Goffart I. Late sexual transmission of Zika virus related to persistence in the semen. Lancet. 2016 18; 387:2501.

  8. Bonaldo MC, Ribeiro IP, Lima NS, Dos Santos AAC, Menezes LSR, da Cruz SOD,  et al.  Isolation of Infective Zika Virus from Urine and Saliva of Patients in Brazil. PLoS Negl Trop Dis. 2016;10(6):e0004816. Available from: DOI: 10.1371/journal.pntd.0004816 PMID:27341420

  9. Fourcade C, Mansuy JM, Dutertre M, Delpech M, Marchou B, Delobel P,  et al.  Viral load kinetics of Zika virus in plasma, urine and saliva in a couple returning from Martinique, French West Indies. J Clin Virol. 2016;82:1-4. DOI: 10.1016/j.jcv.2016.06.011

  10. Perkasa A, Yudhaputri F, Haryanto S, Hayati RF, Ma’roef CN, Antonjaya U,  et al.  Isolation of Zika Virus from Febrile Patient, Indonesia. Emerg Infect Dis. 2016;22(5):924-5. DOI: 10.3201/eid2205.151915

  11. Mansuy JM, Dutertre M, Mengelle C, Fourcade C, Marchou B, Delobel P,  et al.  Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen? Lancet Infect Dis. 2016;16(4):405. DOI: 10.1016/S1473-3099(16)00138-9

  12. Atkinson B, Hearn P, Afrough B, Lumley S, Carter D, Aarons EJ,  et al.  Detection of Zika virus in semen. Emerg Infect Dis. 2016;22(5):940. DOI: 10.3201/eid2205.160107

  13. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual transmission of Zika virus.Emerg Infect Dis. 2015;21(2):359-61. Available from: DOI: 10.3201/eid2102.141363 PMID: 25625872

  14. Barzon L, Pacenti M, Berto A, Sinigaglia A, Franchin E, Lavezzo E,  et al.  Isolation of infectious Zika virus from saliva and prolonged viral RNA shedding in a traveller returning from the Dominican Republic to Italy, January 2016. Euro Surveill. 2016;21(10):30159. DOI: 10.2807/1560-7917.ES.2016.21.10.30159

  15. Liuzzi G, Nicastri E, Puro V, Zumla A, Ippolito G. Zika virus in saliva-New challenges for prevention of human to human transmission. Eur J Intern Med. 2016 May 11. pii: S0953-6205(16)30091-7.

  16. Mate SE, Kugelman JR, Nyenswah TG, Ladner JT, Wiley MR, Cordier-Lassalle T,  et al.  Molecular evidence of sexual transmission of Ebola virus. N Engl J Med. 2015;373(25):2448-54. DOI: 10.1056/NEJMoa1509773

  17. Deen GF, Knust B, Broutet N, Sesay FR, Formenty P, Ross C,  et al.  Ebola RNA persistence in semen of Ebola virus disease survivors – preliminary report. N Engl J Med. 2015;14: Epub ahead of print. DOI: 10.1056/NEJMoa1511410

  18. Huits RMHG, De Smet B, Ariën KK, Van Esbroeck M, de Jong BC, Bottieau E, et al. Kinetics of Zika virus persistence in semen. [Submitted]. Bull World Health Organ. E-pub. 6 Jul 2016. Posted to the Zika open site. http://dx.doi.org/10.2471/BLT.16.181370

  19. European Centre for Disease Prevention and Control (ECDC). Rapid Risk Assessment. Zika virus disease epidemic: Sixth update, 20 May 2016. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/publications/Publications/zika%20virus%20rapid%20risk%20assessment%2010-05-2016.pdf

  20. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS,  et al.  Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360(24):2536-43. DOI: 10.1056/NEJMoa0805715 PMID: 19516034

  21. American Society for Reproductive Medicine (ASRM). Guidance for Providers Caring for Women and Men of Reproductive Age with Possible Zika Virus Exposure (Developed from CDC and FDA Published Guidance). Birmingham, AL: ASRM; 2016. Available from: https://www.asrm.org/uploadedFiles/ASRM_Content/News_and_Publications/News_and_Research/Press_Releases/2016-04/Zika%20Guidance%2004-06-16%20(2).pdf



Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.